Print PDF
Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
March 6, 2015
Brenda Sandburg
The Pink Sheet

Axinn Counsel Stacie Ropka was quoted in The Pink Sheet’s article, “Now Comes the Hard Part: Sandoz Must Sell Its Biosimilar.” The Pink Sheet is produced by Pharma & Med Tech Business Intelligence.  

Click here to access the article.  A subscription is required. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.